Events
We are pleased to inform you that Philipp Bürling has been appointed CEO of Priavoid GmbH as of September 1st, 2020. Philipp holds Master degrees in business informatics and business administration. Before his appointment to Priavoid, he worked in different management positions in the logistics industry for more than a decade. Afterwards, he changed to the biotechnology sector and co-founded NUMAFERM GmbH, an award winning university spin-off focused on the bioproduction of peptides.
Philipp on his new role: „Priavoid has a phenomenal portfolio of drug candidates with an enormous potential not only market-related but especially with regard to highly unmet medical needs. It is an honor to become part of the fight against diseases, such as Alzheimer‘s Disease and a true pleasure to do that together with a great team in the compelling ecosystem of Northrhine Westphalia.“
Priavoid GmbH is a venture capital backed spin-off of the Forschungszentrum Jülich and of the Heinrich Heine University Düsseldorf. We are focused on developing a new class of drugs consisting of all-D-peptides. Our most advanced candidate is PRI-002, which directly disassembles toxic and prion-like Abeta oligomers into harmless Abeta monomers. PRI-002 has demonstrated beneficial efficacy in transgenic and non-transgenic animal models of Alzheimer’s Disease as well as safety in humans in Phase I clinical trials. We are currently seeking funding for a phase II clinical trial of PRI-002 as well as for the advancement of further pipeline candidates and our specialized lead discovery platform.
About Priavoid GmbH:
Priavoid GmbH is a spin-off of Research Center Jülich and Heinrich Heine University Düsseldorf. The company was founded in 2017 and is based in Düsseldorf. It develops novel all-d-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. The most advanced of these is PRI-002 for Alzheimer’s disease. All drug candidates are designed to have an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. The company is privately funded, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner. In addition, the development is significantly supported by the German Federal Agency for Disruptive Innovations, which is funding the PRIMUS-AD phase II study for the drug candidate PRI-002.
